Niaz Banaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Niaz Banaei has a total of 385 co-authors. Here are the top co-authors by number of shared publications:
Indre Budvytiene
Clinical Microbiology Laboratory, Stanford Health Care
30 shared publications- Benjamin A. Pinsky
Department of Pathology, Stanford University School of Medicine, Stanford, USA
10 shared publications Angel Moreno
Department of Pathology, Stanford University School of Medicine
8 shared publicationsFiona Senchyna
Department of Pathology, Stanford University School of Medicine
8 shared publicationsKanagavel Murugesan
Department of Pathology, Stanford University School of Medicine , Stanford, CA
8 shared publications- Kanagavel Murugesan
Department of Pathology, Stanford University School of Medicine
8 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Assessment of BioFire Gastrointestinal Panel unconfirmed positive results for enteropathogenic bacteria and Norovirus and accuracy of a post-analytical algorithm to mitigate unconfirmed results
This study investigated unconfirmed-positive rates with the BioFire FilmArray Gastrointestinal Panel (FAGP) for bacterial targets and Norovirus and determined if melt curve analysis can mitigate unconfirmed results. Positive FAGP results for bacteria were classified as culture-positive or culture-negative and as melt curve-specific or curve-nonspecific. Culture-negative samples were prospectively confirmed with the Xpert GI PCR Panel. Norovirus-positive results were classified as melt curve-specific or curve-nonspecific and confirmed with the Xpert Norovirus PCR. The primary aim was to measure the accuracy of FAGP with and without melt curve analysis. Culture-negative rate was 24.6% (100/407) for Campylobacter jejuni , 90.1% (100/111) for Campylobacter 2 targeting Campylobacter coli and Campylobacter helveticus/upsaliensis , 58.1% (100/172) for Shigella /enteroinvasive Escherichia coli (EIEC), and 38.5% (100/260) for Salmonella spp. Positive predictive value (PPV) of FAGP based on culture and Xpert GI PCR Panel was 100% (42/42) for C. jejuni , 16.7% (4/24) for Campylobacter 2, 94.1% (16/17) for Shigella /EIEC, and 73.2% (30/41) for Salmonella spp. Inclusion of melt curve analysis had no impact on the sensitivity but significantly improved the specificity for Campylobacter spp. from 75% (60/80) to 100% (80/80; P < 0.001), Shigella /EIEC from 98.0% (49/50) to 100% (50/50; P > 0.05), and for Salmonella spp. from 78.0% (39/50) to 96% (48/50; P < 0.01). PPV for Norovirus was 7.6% (7/92) for Norovirus 1 and 76.0% (73/96) for Norovirus 2. Melt curve analysis improved accuracy for Norovirus 2 (sensitivity 100% [73/73] to 98.6% [72/73; P > 0.05]; specificity 79.8% [91/114] to 98.2% [112/114; P < 0.001]) but not for Norovirus 1 (sensitivity 100% [7/7] to 28.6% [2/7; P < 0.01]; specificity 52.0% [92/177] to 100% [177/177; P < 0.001]). FAGP has a high unconfirmed-positive rate for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and Norovirus, which can be partially mitigated with melt curve analysis. IMPORTANCE: The BioFire FilmArray Gastrointestinal Panel is a widely used syndromic panel for rapid diagnosis of gastroenteritis, but recent studies have shown an alarming rate of false-positive results for Norovirus, and concerns have been raised for Campylobacter spp. and other bacterial targets. This study found substantial rates of unconfirmed positive results with the FilmArray Gastrointestinal Panel for Campylobacter spp., Shigella /enteroinvasive Escherichia coli (EIEC), and Salmonella spp. in addition to Norovirus. Through defining specific melt curve parameters, this study shows that it is possible to mitigate unconfirmed positives and assure the quality of results fully for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and partially for Norovirus.
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Open AccessAssessment of BioFire Gastrointestinal Panel unconfirmed positive results for enteropathogenic bacteria and Norovirus and accuracy of a post-analytical algorithm to mitigate unconfirmed results
This study investigated unconfirmed-positive rates with the BioFire FilmArray Gastrointestinal Panel (FAGP) for bacterial targets and Norovirus and determined if melt curve analysis can mitigate unconfirmed results. Positive FAGP results for bacteria were classified as culture-positive or culture-negative and as melt curve-specific or curve-nonspecific. Culture-negative samples were prospectively confirmed with the Xpert GI PCR Panel. Norovirus-positive results were classified as melt curve-specific or curve-nonspecific and confirmed with the Xpert Norovirus PCR. The primary aim was to measure the accuracy of FAGP with and without melt curve analysis. Culture-negative rate was 24.6% (100/407) for Campylobacter jejuni , 90.1% (100/111) for Campylobacter 2 targeting Campylobacter coli and Campylobacter helveticus/upsaliensis , 58.1% (100/172) for Shigella /enteroinvasive Escherichia coli (EIEC), and 38.5% (100/260) for Salmonella spp. Positive predictive value (PPV) of FAGP based on culture and Xpert GI PCR Panel was 100% (42/42) for C. jejuni , 16.7% (4/24) for Campylobacter 2, 94.1% (16/17) for Shigella /EIEC, and 73.2% (30/41) for Salmonella spp. Inclusion of melt curve analysis had no impact on the sensitivity but significantly improved the specificity for Campylobacter spp. from 75% (60/80) to 100% (80/80; P < 0.001), Shigella /EIEC from 98.0% (49/50) to 100% (50/50; P > 0.05), and for Salmonella spp. from 78.0% (39/50) to 96% (48/50; P < 0.01). PPV for Norovirus was 7.6% (7/92) for Norovirus 1 and 76.0% (73/96) for Norovirus 2. Melt curve analysis improved accuracy for Norovirus 2 (sensitivity 100% [73/73] to 98.6% [72/73; P > 0.05]; specificity 79.8% [91/114] to 98.2% [112/114; P < 0.001]) but not for Norovirus 1 (sensitivity 100% [7/7] to 28.6% [2/7; P < 0.01]; specificity 52.0% [92/177] to 100% [177/177; P < 0.001]). FAGP has a high unconfirmed-positive rate for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and Norovirus, which can be partially mitigated with melt curve analysis. IMPORTANCE: The BioFire FilmArray Gastrointestinal Panel is a widely used syndromic panel for rapid diagnosis of gastroenteritis, but recent studies have shown an alarming rate of false-positive results for Norovirus, and concerns have been raised for Campylobacter spp. and other bacterial targets. This study found substantial rates of unconfirmed positive results with the FilmArray Gastrointestinal Panel for Campylobacter spp., Shigella /enteroinvasive Escherichia coli (EIEC), and Salmonella spp. in addition to Norovirus. Through defining specific melt curve parameters, this study shows that it is possible to mitigate unconfirmed positives and assure the quality of results fully for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and partially for Norovirus.
- Open Access
- 2 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Accuracy of plasma cell-free DNA PCR versus mNGS for non-invasive diagnosis of invasive mold disease
Cell-free DNA (cfDNA) detection in plasma is a novel testing modality for non-invasive diagnosis of invasive mold disease (IMD) in immunocompromised patients. The accuracy of PCR compared to metagenomic next-generation sequencing (mNGS) for diagnosis of IMD remains unknown. Plasma samples from patients with proven and probable IMD and no IMD were tested with mold PCR and shotgun mNGS. Mold PCR detected Aspergillus species, Mucorales agents, Fusarium species, Scedosporium species, and Lomentospora prolificans . The sensitivity and specificity of mold PCR and mNGS were measured. Ninety-four patients with proven (48) and probable (48) IMD due to Aspergillus species (64), Mucorales agents (13), Scedosporium species and Lomentospora prolificans (13), and Fusarium species (6), and 62 patients with no IMD were included in this study. 99.4% (155) of the patients were immunosuppressed. The overall sensitivity and specificity were 62.5% (60/96; 95% CI 52.0–72.2) and 99.8% (535/536; 95% CI 99.0–100), respectively, for mold PCR and 43.8% (42/96; 95% CI 33.6–54.3; P < 0.001) and 99.6% (534/536; 95% CI 98.7–100; P = 1.0), respectively, for mNGS. The proportion of mold PCR-positive mNGS-negative results was 16.0% (4/25) in focal cases compared with 25.0% (11/44; P = 0.384) and 18.5% (5/27; P = 0.810) in multifocal and disseminated cases, respectively. The median PCR cycle threshold was 40.6 (IQR, 37.5–41.5) in PCR-positive mNGS-negative cases compared with 37.3 (IQR, 34.5–39.3; P = 0.004) in PCR-positive mNGS-positive cases. Plasma cfDNA PCR is more sensitive than mNGS for the diagnosis of IMD in immunocompromised patients. Lower sensitivity of mNGS was associated with lower mold cfDNA burden. IMPORTANCE: Invasive mold disease (IMD) is a major cause of morbidity and mortality in immunocompromised patients. Early diagnosis and initiation of tailored antifungal therapy are critical for optimizing outcomes in patients with IMD. Detection of circulating fungal cell-free DNA (cfDNA) in the acellular fraction of blood is a novel testing modality that is increasingly used for early and non-invasive diagnosis of IMD. This study represents the first head-to-head accuracy study to compare the sensitivity and specificity of PCR with mNGS for the diagnosis of IMD. The study showed that the overall mold PCR was significantly more sensitive compared with mNGS, while both assays demonstrated very high specificity. Similar trends were observed in a smaller subgroup of patients with invasive aspergillosis, mucormycosis, and scedosporiosis. The findings have implications for assay selection when seeking to non-invasively diagnose IMD in immunocompromised patients.
- 2 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Open AccessAccuracy of plasma cell-free DNA PCR versus mNGS for non-invasive diagnosis of invasive mold disease
Cell-free DNA (cfDNA) detection in plasma is a novel testing modality for non-invasive diagnosis of invasive mold disease (IMD) in immunocompromised patients. The accuracy of PCR compared to metagenomic next-generation sequencing (mNGS) for diagnosis of IMD remains unknown. Plasma samples from patients with proven and probable IMD and no IMD were tested with mold PCR and shotgun mNGS. Mold PCR detected Aspergillus species, Mucorales agents, Fusarium species, Scedosporium species, and Lomentospora prolificans . The sensitivity and specificity of mold PCR and mNGS were measured. Ninety-four patients with proven (48) and probable (48) IMD due to Aspergillus species (64), Mucorales agents (13), Scedosporium species and Lomentospora prolificans (13), and Fusarium species (6), and 62 patients with no IMD were included in this study. 99.4% (155) of the patients were immunosuppressed. The overall sensitivity and specificity were 62.5% (60/96; 95% CI 52.0–72.2) and 99.8% (535/536; 95% CI 99.0–100), respectively, for mold PCR and 43.8% (42/96; 95% CI 33.6–54.3; P < 0.001) and 99.6% (534/536; 95% CI 98.7–100; P = 1.0), respectively, for mNGS. The proportion of mold PCR-positive mNGS-negative results was 16.0% (4/25) in focal cases compared with 25.0% (11/44; P = 0.384) and 18.5% (5/27; P = 0.810) in multifocal and disseminated cases, respectively. The median PCR cycle threshold was 40.6 (IQR, 37.5–41.5) in PCR-positive mNGS-negative cases compared with 37.3 (IQR, 34.5–39.3; P = 0.004) in PCR-positive mNGS-positive cases. Plasma cfDNA PCR is more sensitive than mNGS for the diagnosis of IMD in immunocompromised patients. Lower sensitivity of mNGS was associated with lower mold cfDNA burden. IMPORTANCE: Invasive mold disease (IMD) is a major cause of morbidity and mortality in immunocompromised patients. Early diagnosis and initiation of tailored antifungal therapy are critical for optimizing outcomes in patients with IMD. Detection of circulating fungal cell-free DNA (cfDNA) in the acellular fraction of blood is a novel testing modality that is increasingly used for early and non-invasive diagnosis of IMD. This study represents the first head-to-head accuracy study to compare the sensitivity and specificity of PCR with mNGS for the diagnosis of IMD. The study showed that the overall mold PCR was significantly more sensitive compared with mNGS, while both assays demonstrated very high specificity. Similar trends were observed in a smaller subgroup of patients with invasive aspergillosis, mucormycosis, and scedosporiosis. The findings have implications for assay selection when seeking to non-invasively diagnose IMD in immunocompromised patients.
- 3 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 458-460
Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture
Blood volume impacts the sensitivity of blood culture for diagnosis of bloodstream infection caused by non-fastidious organisms, but its effect on recovery of fastidious organisms is poorly understood. Collecting two Myco/F Lytic bottles, 5 mL of blood each, increased the recovery of fastidious mycobacteria and fungi by 24.1% (7/29).
- 3 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 458-460
Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture
Blood volume impacts the sensitivity of blood culture for diagnosis of bloodstream infection caused by non-fastidious organisms, but its effect on recovery of fastidious organisms is poorly understood. Collecting two Myco/F Lytic bottles, 5 mL of blood each, increased the recovery of fastidious mycobacteria and fungi by 24.1% (7/29).
- Open Access
- 12 May 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e140
Impact of stopping contact precautions on vanA plasmid transmission, Northern California, 2021–2023
Objective: To evaluate the impact of discontinuing contact precautions for vancomycin-resistant enterococci (VRE) on strain and plasmid transmission using long-read whole-genome sequencing (WGS). Study design: Before-after trial of adults with Enterococcus bloodstream infections pre-(Jan–Oct 2021) and post-(Oct–Dec 2021 and Jan–Oct 2023) discontinuation of contact precautions for VRE infections. Setting: Quaternary referral and transplant academic medical center. Patients: Hospitalized adults (≥18 yr) with E. faecalis or E. faecium bacteremia. Methods: Classical epidemiology identified potential transmissions via shared unit exposure within a 14-day window. Blood culture isolates underwent long-read WGS to assess strain and vanA plasmid relatedness. Clonal transmission was defined as P = .679). Genomic analysis identified four clonal transmission events, two of which occurred postdiscontinuation. Among 70 vanA plasmids from 54 patients, 38 highly related plasmids formed a low-diversity cluster. The proportion of cluster plasmids was not significantly different between periods (47% vs 60%; P = .267). Postdiscontinuation, vanA -positive E. faecium ST117 was more prevalent (22/44 vs 53/75; P = .024). Conclusion: Discontinuation of contact precautions for VRE was not associated with increased transmission of enterococci or vanA plasmids in bloodstream infections. Transmission patterns remained largely stable, though the postdiscontinuation period showed increased prevalence of the dominant E. faecium ST117. These findings suggest limited impact of contact precautions on VRE transmission.
- 12 May 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e140
Open AccessImpact of stopping contact precautions on vanA plasmid transmission, Northern California, 2021–2023
Objective: To evaluate the impact of discontinuing contact precautions for vancomycin-resistant enterococci (VRE) on strain and plasmid transmission using long-read whole-genome sequencing (WGS). Study design: Before-after trial of adults with Enterococcus bloodstream infections pre-(Jan–Oct 2021) and post-(Oct–Dec 2021 and Jan–Oct 2023) discontinuation of contact precautions for VRE infections. Setting: Quaternary referral and transplant academic medical center. Patients: Hospitalized adults (≥18 yr) with E. faecalis or E. faecium bacteremia. Methods: Classical epidemiology identified potential transmissions via shared unit exposure within a 14-day window. Blood culture isolates underwent long-read WGS to assess strain and vanA plasmid relatedness. Clonal transmission was defined as P = .679). Genomic analysis identified four clonal transmission events, two of which occurred postdiscontinuation. Among 70 vanA plasmids from 54 patients, 38 highly related plasmids formed a low-diversity cluster. The proportion of cluster plasmids was not significantly different between periods (47% vs 60%; P = .267). Postdiscontinuation, vanA -positive E. faecium ST117 was more prevalent (22/44 vs 53/75; P = .024). Conclusion: Discontinuation of contact precautions for VRE was not associated with increased transmission of enterococci or vanA plasmids in bloodstream infections. Transmission patterns remained largely stable, though the postdiscontinuation period showed increased prevalence of the dominant E. faecium ST117. These findings suggest limited impact of contact precautions on VRE transmission.
- 5 May 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 429-435
Accuracy of Plasma Cell-Free DNA Polymerase Chain Reaction for Diagnosis of Coccidioidomycosis
Background: Coccidioidomycosis is the most prevalent endemic mycosis in the United States. Diagnosis of coccidioidomycosis can be challenging due to limitations of conventional diagnostics. Detection of fungal plasma cell-free DNA (cfDNA) is a novel noninvasive testing modality for the diagnosis of invasive fungal disease. In this study, we characterized the performance of Coccidioides plasma cfDNA polymerase chain reaction (PCR). Methods: A retrospective study was conducted in patients with suspected coccidioidomycosis who underwent plasma cfDNA PCR testing and conventional fungal testing for Coccidioides immitis and Coccidioides posadasii. Patients were categorized per the EORTC/MSGERC case definitions as proven or probable for sensitivity analyses and no coccidioidomycosis for specificity analyses. Results: Overall, 362 plasma samples from unique patients were included in this study. The overall sensitivity, specificity, and positive- and negative-predictive values of Coccidioides plasma cfDNA PCR at 0.04% prevalence were 57.5% (27/47; 95% CI, 42.2%–71.7%), 100% (315/315; 95% CI, 98.8%–100%), 100% (95% CI, 87.2%–100%), and 100% (95% CI, 100%–100%), respectively. The sensitivity was 33.3% (2/6; 95% CI, 4.3%–77.7%) in patients with pulmonary focal disease, 66.7% (14/21; 95% CI, 43.0%–85.4%; P≥.05) in patients with pulmonary multifocal disease, and 52.6% (10/19; 95% CI, 39.6%–77.9%; P≥.05) in patients with disseminated coccidioidomycosis. In patients with concurrent antigen results, the sensitivity of cfDNA PCR was 58.3% (14/24; 95% CI, 39.6%–77.9%) compared with 37.5% (9/24; 95% CI, 18.8%–59.4%; P≥.05) for antigen. Conclusions: Coccidioides plasma cfDNA PCR is modestly sensitive but highly specific, which can be useful for rapid and noninvasive diagnosis of coccidioidomycosis.
- 5 May 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 429-435
Accuracy of Plasma Cell-Free DNA Polymerase Chain Reaction for Diagnosis of Coccidioidomycosis
Background: Coccidioidomycosis is the most prevalent endemic mycosis in the United States. Diagnosis of coccidioidomycosis can be challenging due to limitations of conventional diagnostics. Detection of fungal plasma cell-free DNA (cfDNA) is a novel noninvasive testing modality for the diagnosis of invasive fungal disease. In this study, we characterized the performance of Coccidioides plasma cfDNA polymerase chain reaction (PCR). Methods: A retrospective study was conducted in patients with suspected coccidioidomycosis who underwent plasma cfDNA PCR testing and conventional fungal testing for Coccidioides immitis and Coccidioides posadasii. Patients were categorized per the EORTC/MSGERC case definitions as proven or probable for sensitivity analyses and no coccidioidomycosis for specificity analyses. Results: Overall, 362 plasma samples from unique patients were included in this study. The overall sensitivity, specificity, and positive- and negative-predictive values of Coccidioides plasma cfDNA PCR at 0.04% prevalence were 57.5% (27/47; 95% CI, 42.2%–71.7%), 100% (315/315; 95% CI, 98.8%–100%), 100% (95% CI, 87.2%–100%), and 100% (95% CI, 100%–100%), respectively. The sensitivity was 33.3% (2/6; 95% CI, 4.3%–77.7%) in patients with pulmonary focal disease, 66.7% (14/21; 95% CI, 43.0%–85.4%; P≥.05) in patients with pulmonary multifocal disease, and 52.6% (10/19; 95% CI, 39.6%–77.9%; P≥.05) in patients with disseminated coccidioidomycosis. In patients with concurrent antigen results, the sensitivity of cfDNA PCR was 58.3% (14/24; 95% CI, 39.6%–77.9%) compared with 37.5% (9/24; 95% CI, 18.8%–59.4%; P≥.05) for antigen. Conclusions: Coccidioides plasma cfDNA PCR is modestly sensitive but highly specific, which can be useful for rapid and noninvasive diagnosis of coccidioidomycosis.
- Open Access
Cultryx: Precision Diagnostic Stewardship for Blood Cultures Using Machine Learning
Background: The 2024 blood culture bottle shortage brought diagnostic resource allocation to the forefront, reflecting persistent, foundational challenges with low-value testing and empiric treatment approaches under clinical uncertainty. Objective: To determine whether a machine learning approach using electronic medical record data can predict bacteremia more effectively than existing systems and practices to guide diagnostic testing and empiric treatment strategies. Methods: In a retrospective cohort of 101,812 adult emergency department encounters (2015-2025), we first established an idealized cognitive baseline by evaluating physician and generative AI (GPT-5) application of the professional society-endorsed Fabre framework on a validation subset. We then trained an XGBoost model (Cultryx) on the full cohort to predict bacteremia, benchmarking its performance against real-world clinical heuristics (SIRS, Shapiro Rule). Results: For the idealized baseline, physicians applying the Fabre framework achieved 95.7% sensitivity, but GPT-5 automation failed to replicate this standard (71.6% sensitivity). In real-world benchmarking, Cultryx outperformed all clinical heuristics (AUROC 0.810). SIRS lacked specificity (41.2%), driving diagnostic overuse, while the Shapiro Rule lacked sensitivity (70.2%), missing ~30% of bacteremia cases. In contrast, when calibrated to a strict 95% sensitivity target, Cultryx achieved the highest culture volume deferral rate (26.2%, deferring ~ 15,872 bottles with predicted negative results) while maintaining a 98.9% negative predictive value. Cultryx score , a simplified bedside tool, retained a 20.8% deferral rate. Conclusions: Machine learning provides a superior, data-driven alternative to mainstream clinical heuristics for predicting bacteremia. By maximizing culture deferment without compromising pathogen detection, Cultryx can conserve diagnostic resources, reduce unnecessary empiric antibiotic exposure, and systematically elevate patient safety. Summary: Cultryx, a machine learning model for blood culture stewardship, outperforms standard clinical heuristics in predicting bacteremia. This approach could reduce culture utilization by over 26% while preserving pathogen detection, conserving diagnostic resources, reducing unnecessary antibiotic exposure, and elevating patient safety.
Open AccessCultryx: Precision Diagnostic Stewardship for Blood Cultures Using Machine Learning
Background: The 2024 blood culture bottle shortage brought diagnostic resource allocation to the forefront, reflecting persistent, foundational challenges with low-value testing and empiric treatment approaches under clinical uncertainty. Objective: To determine whether a machine learning approach using electronic medical record data can predict bacteremia more effectively than existing systems and practices to guide diagnostic testing and empiric treatment strategies. Methods: In a retrospective cohort of 101,812 adult emergency department encounters (2015-2025), we first established an idealized cognitive baseline by evaluating physician and generative AI (GPT-5) application of the professional society-endorsed Fabre framework on a validation subset. We then trained an XGBoost model (Cultryx) on the full cohort to predict bacteremia, benchmarking its performance against real-world clinical heuristics (SIRS, Shapiro Rule). Results: For the idealized baseline, physicians applying the Fabre framework achieved 95.7% sensitivity, but GPT-5 automation failed to replicate this standard (71.6% sensitivity). In real-world benchmarking, Cultryx outperformed all clinical heuristics (AUROC 0.810). SIRS lacked specificity (41.2%), driving diagnostic overuse, while the Shapiro Rule lacked sensitivity (70.2%), missing ~30% of bacteremia cases. In contrast, when calibrated to a strict 95% sensitivity target, Cultryx achieved the highest culture volume deferral rate (26.2%, deferring ~ 15,872 bottles with predicted negative results) while maintaining a 98.9% negative predictive value. Cultryx score , a simplified bedside tool, retained a 20.8% deferral rate. Conclusions: Machine learning provides a superior, data-driven alternative to mainstream clinical heuristics for predicting bacteremia. By maximizing culture deferment without compromising pathogen detection, Cultryx can conserve diagnostic resources, reduce unnecessary empiric antibiotic exposure, and systematically elevate patient safety. Summary: Cultryx, a machine learning model for blood culture stewardship, outperforms standard clinical heuristics in predicting bacteremia. This approach could reduce culture utilization by over 26% while preserving pathogen detection, conserving diagnostic resources, reducing unnecessary antibiotic exposure, and elevating patient safety.
- Open Access
- 11 February 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (2) , e0123624
Non-invasive diagnosis of invasive fungal disease with cell-free DNA PCR
Invasive fungal disease (IFD) is a major cause of morbidity and mortality in the immunocompromised population. Early diagnosis is challenging due to the low sensitivity and non-specificity of non-invasive fungal biomarkers, the need for invasive specimen collection, and the limitations of culture and histopathology. Detection of circulating fungal cell-free DNA (cfDNA) in plasma and serum by polymerase chain reaction (PCR) represents a novel testing modality for rapid and accurate diagnosis of IFD. In this review, we summarize the performance characteristics of fungal cfDNA PCR for the diagnosis of invasive aspergillosis, mucormycosis, and Pneumocystis pneumonia. We discuss a testing algorithm that incorporates fungal cfDNA and the added diagnostic value of invasive specimen collection when non-invasive mold cfDNA PCR is performed first. Lastly, we discuss the role of diagnostic stewardship in fungal cfDNA PCR testing.
- 11 February 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (2) , e0123624
Open AccessNon-invasive diagnosis of invasive fungal disease with cell-free DNA PCR
Invasive fungal disease (IFD) is a major cause of morbidity and mortality in the immunocompromised population. Early diagnosis is challenging due to the low sensitivity and non-specificity of non-invasive fungal biomarkers, the need for invasive specimen collection, and the limitations of culture and histopathology. Detection of circulating fungal cell-free DNA (cfDNA) in plasma and serum by polymerase chain reaction (PCR) represents a novel testing modality for rapid and accurate diagnosis of IFD. In this review, we summarize the performance characteristics of fungal cfDNA PCR for the diagnosis of invasive aspergillosis, mucormycosis, and Pneumocystis pneumonia. We discuss a testing algorithm that incorporates fungal cfDNA and the added diagnostic value of invasive specimen collection when non-invasive mold cfDNA PCR is performed first. Lastly, we discuss the role of diagnostic stewardship in fungal cfDNA PCR testing.
- Open Access
- 17 December 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (12) , e0114525
Accuracy and actionability of mold PCR on bronchoalveolar lavage fluid for diagnosis of invasive mold disease
Bronchoalveolar lavage fluid (BAL) is commonly obtained for diagnosing invasive mold disease (IMD) in immunocompromised patients. This study investigated the accuracy, turnaround time, and clinical actionability of mold polymerase chain reaction (PCR) on BAL. All BAL tested with mold PCR and fungal culture during the study period were included in this study. The mold PCR detected Aspergillus species, Mucorales agents, Fusarium species, and Scedosporium spp./ Lomentospora prolificans . Cases were classified per the EORTC/MSGERC definitions. The sensitivity, specificity, turnaround time, and actionability of the mold PCR were measured. Out of 1,958 BAL samples tested, mold PCR was positive in 160 (8.2%) and culture in 75 (3.8%). Mold PCR was most commonly positive for Aspergillus species (77.5%), followed by Scedosporium spp./ L. prolificans (20.0%), Mucorales agents (8.3%), and Fusarium species (1.2%). The sensitivity and specificity of the mold PCR using culture as the reference standard were 92.0% (69/75, 95% CI 83.4–97.1) and 95.2% (1794/1883, 95% CI 94.2–96.2), respectively. In 32 proven IMD cases, the sensitivity of mold PCR panel and culture was 90.6% (29/32, 95% CI 74.9–98.1) and 56.3% (18/32, 95% CI 37.7–73.7) ( P < 0.001), respectively. The median time to positivity for mold PCR and culture was 1 day (interquartile range [IQR] 1–2) and 3 days (IQR 2–4) ( P < 0.001), respectively. Among positive mold PCR results that provided a new finding ( n = 91), 65.9% were clinically actionable. Mold PCR performed on BAL was more sensitive and rapid compared with fungal culture, and positive results were highly actionable. IMPORTANCE: Invasive mold disease (IMD) in immunocompromised patients is associated with high morbidity and mortality. Bronchoalveolar lavage fluid (BAL) is commonly obtained for diagnosing pulmonary IMD, but rapid and accurate diagnosis of IMD is challenging with conventional diagnostics. The aim of this study was to investigate the accuracy, turnaround time, and clinical actionability of a BAL mold PCR assay detecting the five most common genera causing IMD. The BAL mold PCR was highly sensitive and specific compared to BAL fungal culture used as the reference method. In patients with proven pulmonary IMD, the BAL mold PCR was highly sensitive and significantly more sensitive compared with fungal culture. The BAL mold PCR was significantly more rapid than fungal culture, and the results were highly actionable. Overall, findings indicate the BAL mold PCR is highly accurate, rapid, and actionable for diagnosis of pulmonary IMD.
- 17 December 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (12) , e0114525
Open AccessAccuracy and actionability of mold PCR on bronchoalveolar lavage fluid for diagnosis of invasive mold disease
Bronchoalveolar lavage fluid (BAL) is commonly obtained for diagnosing invasive mold disease (IMD) in immunocompromised patients. This study investigated the accuracy, turnaround time, and clinical actionability of mold polymerase chain reaction (PCR) on BAL. All BAL tested with mold PCR and fungal culture during the study period were included in this study. The mold PCR detected Aspergillus species, Mucorales agents, Fusarium species, and Scedosporium spp./ Lomentospora prolificans . Cases were classified per the EORTC/MSGERC definitions. The sensitivity, specificity, turnaround time, and actionability of the mold PCR were measured. Out of 1,958 BAL samples tested, mold PCR was positive in 160 (8.2%) and culture in 75 (3.8%). Mold PCR was most commonly positive for Aspergillus species (77.5%), followed by Scedosporium spp./ L. prolificans (20.0%), Mucorales agents (8.3%), and Fusarium species (1.2%). The sensitivity and specificity of the mold PCR using culture as the reference standard were 92.0% (69/75, 95% CI 83.4–97.1) and 95.2% (1794/1883, 95% CI 94.2–96.2), respectively. In 32 proven IMD cases, the sensitivity of mold PCR panel and culture was 90.6% (29/32, 95% CI 74.9–98.1) and 56.3% (18/32, 95% CI 37.7–73.7) ( P < 0.001), respectively. The median time to positivity for mold PCR and culture was 1 day (interquartile range [IQR] 1–2) and 3 days (IQR 2–4) ( P < 0.001), respectively. Among positive mold PCR results that provided a new finding ( n = 91), 65.9% were clinically actionable. Mold PCR performed on BAL was more sensitive and rapid compared with fungal culture, and positive results were highly actionable. IMPORTANCE: Invasive mold disease (IMD) in immunocompromised patients is associated with high morbidity and mortality. Bronchoalveolar lavage fluid (BAL) is commonly obtained for diagnosing pulmonary IMD, but rapid and accurate diagnosis of IMD is challenging with conventional diagnostics. The aim of this study was to investigate the accuracy, turnaround time, and clinical actionability of a BAL mold PCR assay detecting the five most common genera causing IMD. The BAL mold PCR was highly sensitive and specific compared to BAL fungal culture used as the reference method. In patients with proven pulmonary IMD, the BAL mold PCR was highly sensitive and significantly more sensitive compared with fungal culture. The BAL mold PCR was significantly more rapid than fungal culture, and the results were highly actionable. Overall, findings indicate the BAL mold PCR is highly accurate, rapid, and actionable for diagnosis of pulmonary IMD.
- Open Access
- 8 October 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (10) , e0089625
Diagnostic stewardship applied to targeted fungal sequencing
- 8 October 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (10) , e0089625
Open AccessDiagnostic stewardship applied to targeted fungal sequencing
- Open Access
- 13 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (8) , e0079625
Accuracy of plasma cell-free DNA PCR for non-invasive diagnosis of mucormycosis
Diagnosis of mucormycosis poses a substantial challenge due to the lack of a non-invasive biomarker and limitations of conventional diagnostics using invasive specimens. The aim of this study was to characterize the performance of Mucorales plasma cell-free DNA (cfDNA) PCR in immunosuppressed and non-immunosuppressed patients with pulmonary, disseminated, and localized mucormycosis. Patients with Mucorales plasma cfDNA test results were retrospectively categorized as proven or probable for sensitivity analysis and as no Mucorales infection for specificity analysis. In total, 85 positive and 212 negative Mucorales plasma cfDNA test results in unique patients were included in this study. Per the expert definitions, 47 patients had proven or probable mucormycosis, and 171 did not have invasive Mucorales infection. The Mucorales plasma cfDNA PCR had an overall sensitivity and specificity of 85.1% (40/47, 95% CI, 71.7–93.8) and 92.9% (158/170, 95% CI, 88.0–96.3), respectively. The sensitivity was 92.1% (35/38, 95% CI, 78.6–98.3) and 55.6% (5/9, 95% CI, 21.2–86.3) in patients with and without immunosuppression, respectively, and 100% (14/14, 95% CI, 76.8–100), 89.5% (17/19, 95% CI, 66.9–98.7), and 64.3% (9/14, 95% CI, 35.1–87.2) in patients with disseminated, pulmonary, and localized mucormycosis, respectively. Mucorales plasma cfDNA PCR is a sensitive and specific non-invasive testing modality for the diagnosis of mucormycosis in immunosuppressed patients and those with pulmonary and disseminated infection. IMPORTANCE: Mucormycosis is an invasive mold infection associated with high morbidity and mortality. Early diagnosis and effective antifungal treatment are critical for improving clinical outcomes. However, diagnosis of mucormycosis is often delayed due to the lack of a non-invasive biomarker and insensitivity of culture and non-specificity of histopathology performed on invasive specimens. Mucorales plasma cell-free DNA (cfDNA) PCR is a novel testing modality that allows non-invasive diagnosis of mucormycosis. In the current study, we evaluated the clinical performance of a pre-analytically optimized Mucorales plasma cfDNA PCR in immunosuppressed and non-immunosuppressed patients with pulmonary, disseminated, and localized infections. We show that Mucorales plasma cfDNA PCR is highly sensitive and specific in immunosuppressed patients with pulmonary and disseminated infections. Thus, the Mucorales plasma cfDNA PCR represents an accurate diagnostic tool for non-invasive diagnosis of mucormycosis, which may enable early treatment and improved outcomes in immunosuppressed patients with mucormycosis.
- 13 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (8) , e0079625
Open AccessAccuracy of plasma cell-free DNA PCR for non-invasive diagnosis of mucormycosis
Diagnosis of mucormycosis poses a substantial challenge due to the lack of a non-invasive biomarker and limitations of conventional diagnostics using invasive specimens. The aim of this study was to characterize the performance of Mucorales plasma cell-free DNA (cfDNA) PCR in immunosuppressed and non-immunosuppressed patients with pulmonary, disseminated, and localized mucormycosis. Patients with Mucorales plasma cfDNA test results were retrospectively categorized as proven or probable for sensitivity analysis and as no Mucorales infection for specificity analysis. In total, 85 positive and 212 negative Mucorales plasma cfDNA test results in unique patients were included in this study. Per the expert definitions, 47 patients had proven or probable mucormycosis, and 171 did not have invasive Mucorales infection. The Mucorales plasma cfDNA PCR had an overall sensitivity and specificity of 85.1% (40/47, 95% CI, 71.7–93.8) and 92.9% (158/170, 95% CI, 88.0–96.3), respectively. The sensitivity was 92.1% (35/38, 95% CI, 78.6–98.3) and 55.6% (5/9, 95% CI, 21.2–86.3) in patients with and without immunosuppression, respectively, and 100% (14/14, 95% CI, 76.8–100), 89.5% (17/19, 95% CI, 66.9–98.7), and 64.3% (9/14, 95% CI, 35.1–87.2) in patients with disseminated, pulmonary, and localized mucormycosis, respectively. Mucorales plasma cfDNA PCR is a sensitive and specific non-invasive testing modality for the diagnosis of mucormycosis in immunosuppressed patients and those with pulmonary and disseminated infection. IMPORTANCE: Mucormycosis is an invasive mold infection associated with high morbidity and mortality. Early diagnosis and effective antifungal treatment are critical for improving clinical outcomes. However, diagnosis of mucormycosis is often delayed due to the lack of a non-invasive biomarker and insensitivity of culture and non-specificity of histopathology performed on invasive specimens. Mucorales plasma cell-free DNA (cfDNA) PCR is a novel testing modality that allows non-invasive diagnosis of mucormycosis. In the current study, we evaluated the clinical performance of a pre-analytically optimized Mucorales plasma cfDNA PCR in immunosuppressed and non-immunosuppressed patients with pulmonary, disseminated, and localized infections. We show that Mucorales plasma cfDNA PCR is highly sensitive and specific in immunosuppressed patients with pulmonary and disseminated infections. Thus, the Mucorales plasma cfDNA PCR represents an accurate diagnostic tool for non-invasive diagnosis of mucormycosis, which may enable early treatment and improved outcomes in immunosuppressed patients with mucormycosis.